目的　探讨 P糖蛋白 (P- gp)和 p5 3蛋白在结肠腺癌中的表达意义。　方法　应用免疫组织化学方法检测术前未进行化疗的 140例结肠癌组织中的多药耐药基因产物 P- gp和 p5 3蛋白的表达。　结果　 P- gp和 p5 3在结肠癌中的表达分别为 2 3.5 7% (33/ 140 )和 40 % (5 6 / 140 )。P- gp表达与结肠癌的组织学类型、浸润深度和淋巴结转移状况无关 (P>0 .0 5 ) ;而 p5 3除与淋巴结转移状况有关外 (P<0 .0 5 ) ,与组织学类型和浸润深度无关 (P>0 .0 5 )。P- gp在 p5 3阳性的病例中的表达明显高于 p5 3阴性者 (P<0 .0 1)。　结论　 P- gp和 p5 3协同表达于结肠癌组织中 ,可作为结肠癌病人的临床耐药和预后判断的可靠指标 Objective To investigate the expression of P-glycoprotein (P-gp) and p53 proteins in human colon adenocarcinoma. Methods Immunohistochemistry was used to detect the expression of multidrug resistance gene products P-gp and p5 3 in 140 cases without chemotherapy. Results The expressions of P-gp and p5 3 in colon cancer were 23.5% (33/140) and 40% (56/140), respectively. The expression of P-gp was not associated with histological type, depth of invasion and lymph node metastasis (P> 0.05), while p5 3 was not associated with lymph node metastasis (P <0.05) The type and infiltration depth have nothing to do (P> 0.05). The expression of P-gp in p5-3-positive cases was significantly higher than that in p5-3-negative patients (P <0.01). Conclusions P-gp and p53 co-expression in colon cancer tissue can be used as a reliable indicator of clinical drug resistance and prognosis in patients with colon cancer